D. Boral Capital Reaffirms “Buy” Rating for Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio (NASDAQ:TVGN)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Tevogen Bio Stock Down 4.0 %

NASDAQ TVGN opened at $0.98 on Monday. The business has a 50-day moving average price of $1.19 and a 200-day moving average price of $1.30. Tevogen Bio has a twelve month low of $0.26 and a twelve month high of $3.09.

Insider Transactions at Tevogen Bio

In other Tevogen Bio news, insider Neal Flomenberg sold 88,519 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90. Following the completion of the transaction, the insider now owns 4,040,485 shares of the company’s stock, valued at $4,444,533.50. This represents a 2.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have sold 406,510 shares of company stock valued at $446,763. 56.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tevogen Bio

Large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in Tevogen Bio during the 4th quarter valued at approximately $38,000. JPMorgan Chase & Co. boosted its position in shares of Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after acquiring an additional 16,695 shares during the last quarter. Barclays PLC grew its holdings in shares of Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after purchasing an additional 12,847 shares in the last quarter. XTX Topco Ltd bought a new stake in Tevogen Bio in the fourth quarter worth $55,000. Finally, Northern Trust Corp raised its stake in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after purchasing an additional 13,595 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.